

Henry Ford Health

Henry Ford Health Scholarly Commons

Allergy & Immunology Meeting Abstracts

Allergy and Immunology

2-1-2023

The Effect of Subcutaneous German Cockroach Immunotherapy (SCIT) on Nasal Allergen Challenge (NAC) and Cockroach-specific Antibody Responses Among Urban Children and Adolescents

Edward M. Zoratti

Robert Wood

George O'Connor

Jacqueline Pongracic

Melanie Makhija

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/allergy_mtgabstracts

Authors

Edward M. Zoratti, Robert Wood, George O'Connor, Jacqueline Pongracic, Melanie Makhija, Gurjit K. Hershey, Michael Sherenian, Michelle Gill, Rebecca Gruchalla, Jeffrey Chambliss, Andrew Liu, Meyer Kattan, Paula Busse, Leonard Bacharier, Katherine Rivera-Spoljaric, William Sheehan, Daniel Jackson, Peter Gergen, Alkis Togias, Agustin Calatroni, Cynthia Visness, Kate Cho, Alessandro Sette, Matthew Altman, and William Busse

L10 The Effect of Subcutaneous German Cockroach Immunotherapy (SCIT) on Nasal Allergen Challenge (NAC) and Cockroach-specific Antibody Responses Among Urban Children and Adolescents



Edward Zoratti, MD, FAAAAI¹, Robert Wood, MD, MD FAAAAI², George O, MD³, Jacqueline Pongracic⁴, Melanie Makhija, MD, MS⁵, Gurjit Khurana Hershey, MD PhD FAAAAI⁶, Michael Sherenian, MD⁶, Michelle Gill, MD, PhD⁷, Rebecca Gruchalla, MD PhD FAAAAI⁸, Jeffrey Chambliss, MD⁹, Andrew Liu, MD FAAAAI¹⁰, Meyer Kattan¹¹, Paula Busse, MD FAAAAI¹², Leonard Bacharier, MD FAAAAI¹³, Katherine Rivera-Spoljaric, MD⁷, William Sheehan, MD FAAAAI¹⁴, Daniel Jackson, MD FAAAAI¹⁵, Peter Gergen, MD MPH¹⁶, Alkis Togias, MD FAAAAI¹⁷, Agustin Calatroni, MA MS¹⁸, Cynthia Visness, PhD, MPH¹⁸, Kate Cho¹⁸, Alessandro Sette, PhD¹⁹, Matthew Altman, MD²⁰, William Busse, MD FAAAAI¹⁵, ¹Henry Ford Health, Detroit, MI, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Boston University School of Medicine, Boston, MA, ⁴Ann & Robert H. Lurie Children's Hospital, Chicago, IL, ⁵Ann and Robert H Lurie Children's Hospital, Chicago, IL, ⁶Cincinnati Children's Hospital, Cincinnati, OH, ⁷St. Louis Children's Hospital, Saint Louis, MO, ⁸Univ. Texas Southwestern Medical Center, Dallas, TX, ⁹University of Texas Southwestern Medical Center, Dallas, TX, ¹⁰Children's Hospital of Colorado, University of Colorado, School of Medicine, Aurora, CO, ¹¹Columbia University Medical Center, New York, NY, ¹²Icahn School of Medicine at Mount Sinai, New York, NY, ¹³Monroe Carell Jr. Children's Hospital at Vanderbilt University Medical Center, Nashville, TN, ¹⁴Children's National Medical Center, Washington, DC, ¹⁵University of Wisconsin School of Medicine, Madison, WI, ¹⁶NIH/NIAID, Rockville, MD, ¹⁷NIAID/NIH, Rockville, MD, ¹⁸Rho Federal Systems Division, Durham, NC, ¹⁹La Jolla Institute for Immunology, LaJolla, CA, ²⁰University of Washington, Seattle, WA.

RATIONALE: Cockroach allergy contributes to asthma and rhinitis morbidity among many urban children. Treatment with cockroach SCIT could be beneficial.

METHODS: 8-17 year-old children with mild-moderate asthma from 11 urban sites participated in a randomized double-blind placebo-controlled SCIT trial using non-standardized, glycerinated German cockroach extract. Positive cockroach skin tests, cockroach-specific IgE, and nasal challenge response with total nasal symptom scores (TNSS) ≥ 6 or maximal sneeze scores of 3 during a graded NAC were required for enrollment. Following dose escalation, 0.4 ml of undiluted extract was targeted for maintenance dosing (~7 mcg Bla g2/dose). The primary endpoint was change in NAC-induced mean TNSS from baseline to one year post randomization. Changes in cockroach-specific IgE (CRsIgE) and IgG4 (CRsIgG4) were also analyzed.

RESULTS: Mean TNSS did not significantly change from baseline in either group (placebo n=29, SCIT n=28). There was no significant difference in the change in mean TNSS between placebo and SCIT [-0.79 ± 0.35 vs. -1.02 ± 0.37 , respectively, difference=0.2(-1.15, 0.70), p=0.63]. Baseline CRsIgE and CRsIgG4 didn't differ between groups. Mean CRsIgE decreased in both groups following treatment: 3.6 to 2.3 kU/L (0.64 fold change), p=0.015 and 8.3 to 4.2 kU/L (0.51 fold change), p<0.001 in placebo and SCIT respectively, but did not differ between groups [p=0.33]. Significant increases in CRsIgG4 post-treatment were observed among SCIT recipients only: 0.07 to 12.3 mg/L (176 fold change), p<0.001.

CONCLUSIONS: Cockroach SCIT increased CRsIgG4 levels but did not significantly alter NAC-induced TNSS responses. The extent to which NAC in these children may reflect clinical efficacy for rhinitis or asthma is uncertain.

L11 The Pediatric Asthma Risk Score: A New Gold Standard for Asthma Prediction



Jocelyn Biagini, PhD¹, Lisa Martin, PhD², Hua He, MS¹, Leonard Bacharier, MD FAAAAI³, Tebeb Gebretsadik³, Tina Hartert, MD MPH⁴, Daniel Jackson, MD FAAAAI⁵, Haejin Kim, MD⁶, Rachel Miller, MD FAAAAI⁷, Katherine Rivera-Spoljaric, MD⁸, Eric Schaubberger, PhD, DO⁹, Anne Marie Singh, MD¹⁰, Cynthia Visness, PhD, MPH¹¹, Ganesa Wegienka, PhD FAAAAI⁶, Dennis Ownby, MD FAAAAI¹², Diane Gold, MD¹³, Fernando Martinez, MD¹⁴, Christine Cole Johnson, PhD MPH FAAAAI⁶, Anne Wright¹⁵, James Gern, MD FAAAAI¹⁰, Gurjit Khurana Hershey, MD PhD FAAAAI¹⁶; ¹Cincinnati Children's Hospital Medical Center, ²Cincinnati Children, ³Vanderbilt University Medical Center, ⁴Vanderbilt University, ⁵University of Wisconsin-Madison, ⁶Henry Ford Health System, ⁷Icahn School of Medicine at Mount Sinai, ⁸St. Louis Children, ⁹University of Wisconsin - Madison, ¹⁰University of Wisconsin School of Medicine and Public Health, ¹¹Rho, Inc., ¹²Augusta University, ¹³Channing Division of Network Medicine, ¹⁴University of Arizona, ¹⁵Arizona Respiratory Science Center, ¹⁶Children.

RATIONALE: Early prediction of asthma is critical to identify potential primary prevention strategies. The Pediatric Asthma Risk Score (PARS) is a continuous score to predict early-life asthma but was developed and validated in relatively homogenous populations. We compared PARS directly to the Asthma Predictive Index (API) and validated in 10 cohorts with varying race, ethnicity, sex, cohort type, missing data and birth decades, and perform a meta-analysis across all 10 cohorts.

METHODS: We utilized data from 5674 children participating in the Children's Respiratory and Environmental Workgroup. We applied both PARS and the API in each cohort, as well as harmonized across all cohorts, and directly compared the ability of each tool to predict asthma development at ages 5-10.

RESULTS: The PARS area under the curve (AUC) was significantly higher than the AUC of the API in 9 cohorts (p-value range 0.01 - <0.001). The PARS AUC did not differ by cohort type (high risk or general population), decade of enrollment, race, sex, ethnicity, missing PARS factors or polysensitization definition (skin prick test vs. specific IgE). The weights of the 6 PARS factors in the meta-analysis were very similar to the original weights, validating the original PARS scoring.

CONCLUSIONS: This multi-cohort study makes the PARS the most validated model of asthma prediction in children to date, not only with respect to the number of cohorts used but also with regards to capturing the diversity of asthma in the United States. Future studies may consider PARS the new gold standard in pediatric asthma risk prediction.